Novo Nordisk's $1.1 Billion Deal to Expand Cardiovascular Pipeline
Novo Nordisk has agreed to acquire Cardior Pharmaceuticals for up to $1.1 billion in a move to expand its cardiovascular pipeline, aligning with its focus on diabetes and weight-loss therapies. The deal includes Cardior's lead compound CDR132L, currently in Phase II trials for heart failure, with plans to start a second Phase II trial for cardiac hypertrophy. The acquisition is expected to close in the second quarter of 2024 and will not impact Novo's 2024 operating profit guidance.
